BMY ▲ +4.6% - Bristol-Myers Squibb Company
$BMY Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint
12-OCT-2026 06:52 AM ET
Share this post
More filings for $BMY
BMY ▲ +4.6% - Bristol-Myers Squibb CompanyOct 12, 2026BMY ▲ +0.2% - Bristol-Myers Squibb CompanyOct 8, 2026BMY ▼ -2.1% - Bristol-Myers Squibb CompanySep 29, 2026BMY ▼ -2.1% - Bristol-Myers Squibb CompanySep 29, 2026BMY ▲ +0.6% - Bristol-Myers Squibb CompanySep 25, 2026BMY ▼ -0.9% - Bristol-Myers Squibb CompanySep 8, 2026
View full $BMY filing history →💬 Comments
Loading comments…
Leave a comment